Virginia Giuffre's memoir reveals intimate details about her family life, children Trump Signs Spending Bill, Ending Longest ...

DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...

Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action in the U.S. District Court for the Southern District of New York alleging violations ...

Morgan Stanley lowered the firm’s price target on DexCom (DXCM) to $63 from $89 and keeps an Overweight rating on the shares. Published first on ...